Tags
- 2027
- A
- Abandon
- ACCE
- Acid
- ADC
- Adenosine diphosphate ribose
- Advanced
- An
- Analysis
- Annual report
- Antagonist
- Antibodies
- Antibody-drug conjugate
- Apoptosis
- Application
- Approximately
- April Merck
- Biopharmaceutical
- Cancer
- Cancer Cell
- Carcinoma
- Cell
- Centre
- Chemoradiotherapy
- Chemotherapy
- Chinese
- Chinese company
- Clinical endpoint
- Combination
- Company profile
- Company profiles
- Compatibility
- Competition
- Competitive advantage
- Competitors
- Comprehensive
- Conduct
- Conjugate
- Darmstadt
- Data
- Data monitoring
- Data monitoring committee
- Deal
- Debiopharm
- Drug
- Edge
- End-of-life
- Endpoint
- Endpoints
- Epithelium
- Event-free survival
- Exchange
- Failure
- Five
- Following
- Frankfurt
- Frankfurt Stock Exchange
- Gain
- Germany
- Global headquarters
- Goal
- Head and neck anatomy
- Head and neck cancer
- Headquarters
- Hour
- Hours
- IAP
- In-depth review
- Informed
- Inhibitor
- Inhibitor of apoptosis
- In-phase and quadrature components
- Interim
- Interim analysis
- International
- Investment
- Jiangsu
- Life science
- Limited Partnership
- Local property
- Market
- Merck
- Merck Group
- Messenger
- Messenger RNA
- Monitoring
- Most
- Multiple sclerosis
- New
- New Life
- Oncology
- Over
- PARP1
- Participation
- Patient
- Performance
- Pharmaceutical drug
- Phase
- Phase II
- Phase III
- Phases of clinical research
- Placebo
- Placebo-controlled study
- Polymerase
- Portfolio
- Primary
- Primary endpoints
- Profile
- Profiles
- Properties
- Protein
- Quick
- Randomization
- Research
- Research center
- Responsibility
- Restore
- Result
- Safety
- Save
- Science
- Science research
- Sclerosis
- Selective
- Sensitivity
- Sensitization
- Squamous cell carcinoma
- Stock
- Stock exchange
- Survival
- Termination
- The independent
- Therapy
- The trial
- Tithe
- Trade
- Trapping
- Trial
- Trials
- Unlikely
- Versus